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Background: The use of liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
has substantially increased in clinical laboratories worldwide. To assess the status of clinical 
LC-MS/MS testing in Korean laboratories, a questionnaire survey was performed by the Clini-
cal Mass Spectrometry Research Committee of the Korean Society of Clinical Chemistry.
Methods: The questionnaire was distributed to 19 clinical laboratories performing clinical 
LC-MS/MS from April to May 2018. It asked about general characteristics of the laboratory 
and commonly utilized clinical LC-MS/MS tests: newborn screening, tacrolimus test, vita-
min D test, and plasma metanephrine test. Frequency analysis and other statistical analy-
ses were performed. 
Results: A total of 17 laboratories responded. The median number of LC-MS/MS instru-
ments, laboratory medicine physicians, and technicians in each laboratory was three, one, 
and two, respectively. Nine laboratory directors had >10 years of experience with clinical 
LC-MS/MS. For each LC-MS/MS test, at least two concentrations of QC materials were 
measured every 24 hours during clinical testing, and all laboratories used QC acceptability 
criteria based on their established QC means and SDs. All laboratories participated in an 
external quality assessment program. However, there was inter-laboratory variability in sam-
ple preparation methods, instruments, reagents, internal standards, and calibrators. 
Conclusions: LC-MS/MS has been successfully introduced in Korean clinical laboratories 
and is used within a quality framework. Further efforts for harmonization on a nationwide 
basis could facilitate the widespread use of LC-MS/MS. 
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INTRODUCTION
Mass spectrometry (MS) represents a key technology in biomed-
ical research areas, such as proteomics, pharmacology, and 
metabolomics [1]. With the advent of soft ionization techniques, 
such as electrospray ionization (ESI) and matrix-assisted laser 
desorption ionization (MALDI), the use of liquid chromatogra-
phy-tandem MS (LC-MS/MS) has substantially increased in clini-
cal laboratories [2, 3]. Current clinical applications of LC-MS/MS 
include screening for inherited metabolic disorders, measure-
ment of numerous small-molecule biomarkers, and quantifica-
tion of drugs and their metabolites [1]. The strengths of LC-MS/
MS are its high selectivity and sensitivity, capability for multi-an-
alyte analyses, and high throughput. 
As an effort to popularize and improve the use of LC-MS/MS 
in clinical laboratories across Korea, a questionnaire survey was 
conducted by the Clinical Mass Spectrometry Research Commit-
tee (CMSRC) of the Korean Society of Clinical Chemistry (KSCC). 
It aimed to provide an accurate and updated overview of clinical 
LC-MS/MS testing in Korean clinical laboratories and shed light 
on the challenges of using LC-MS/MS in this setting. 
METHODS
Survey population 
The survey population consisted of all 19 clinical laboratories 
performing clinical LC-MS/MS tests in medical institutions (hos-
pitals and medical centers) and referral medical laboratories ac-
credited by the Korean Laboratory Accreditation Program (KO-
LAS) [4]. The survey was performed from April to May 2018. The 
questionnaire was e-mailed to the directors and laboratory phy-
sicians in charge of these 19 laboratories. This study was ap-
proved by the Institutional Review Board (IRB)/Ethics Commit-
tee of Seoul St. Mary’s Hospital, Korea (IRB No. KC18QCDI0566).
Questionnaire
The questionnaire was in Korean, with multiple-choice ques-
tions, and consisted of two sections. The first comprised ques-
tions on the general characteristics of the LC-MS/MS laboratory: 
type of medical institution; number of LC-MS/MS instruments; 
number of LC-MS/MS laboratory physicians, technicians, and 
researchers; years of experience with clinical LC-MS/MS tests; 
clinical LC-MS/MS tests performed; laboratory area; and instru-
ment management (nitrogen gas supply and preventive mainte-
nance plans). 
The second section comprised questions on four commonly 
utilized clinical diagnostic tests: newborn screening test (NST), 
tacrolimus test, vitamin D test, and plasma metanephrine test. 
The questionnaire asked about sample pretreatment and sam-
ple volume, test volume, turnaround time (TAT), testing frequency, 
calibrators, internal standards, reagents, internal quality control, 
test reporting, proficiency testing, and components of method 
validation. 
Data analysis
An Excel spreadsheet was used to summarize the data. Cate-
gorical data were summarized as frequency and percentage, 
Table 1. Clinical LC-MS/MS tests performed in 17 clinical laborato-
ries in Korea 
Laboratories, N (%)
Newborn screening 
   Amino acid/organic acid/fatty acid disorders 11 (65)
   Galactosemia 2 (12)
   Krabbe disease 1 (6)
   Lysosomal storage disorders 3 (18)
Therapeutic drug monitoring
   Immunosuppressants 9 (53)
   Anti-infective agents 6 (35)
   Anticonvulsants 6 (35)
   Antidepressants/antipsychotics 2 (12)
   Anticancer agents 2 (12)
   Amiodarone 1 (6)
Drugs of abuse 3 (18)
Metabolite/hormones
   5-HIAA 1 (6)
   Metanephrines 7 (41)
   Amino acids 3 (18)
   Acylcarnitines 2 (12)
   Carnitine 3 (18)
   Homocysteine 4 (24)
   Methylmalonic acid 1 (6)
   Citrate 1 (6)
   Oxalate 1 (6)
   Steroid profile 1 (6)
   Cortisol 1 (6)
   Catecholamines 2 (12)
   Aldosterone 2 (12)
Vitamin D 9 (53)
Abbreviations: LC-MS/MS, liquid chromatography-tandem mass spectrome-
try; HIAA, hydroxyindoleacetic acid.
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and continuous data were summarized as median and range. 
Normality was assessed using the D’Agostino and Pearson nor-
mality test. The association between the types of the clinical 
laboratory and TAT or test volume was evaluated using Fisher’s 
exact tests. The correlation between the number of LC-MS/MS 
instruments and the number of laboratory medicine physicians, 
the number of laboratory technicians, and the number of clini-
cal LC-MS/MS tests was assessed using Pearson’s correlation 
coefficient. GraphPad Prism 7.05 (GraphPad Software, San Di-
ego, CA, USA) was used for statistical analyses. P <0.05 was 
considered statistically significant.
RESULTS
Laboratory characteristics 
Seventeen laboratories (11 university hospitals and six referral 
medical laboratories) responded. The median number of LC-
MS/MS instruments was three (range, 1–10). The median num-
ber of laboratory medicine physicians was one (range, 1–3), and 
the median number of laboratory technicians was two (range, 
1–5). Nine laboratory directors had >10 years and 35% had 
5–10 years of experience with clinical LC-MS/MS tests (for a list 
of tests, see Table 1). 
When the general characteristics of LC-MS/MS clinical labora-
tories were compared according to the type of institution, the 
median number of LC-MS/MS instruments was higher in referral 
medical laboratories than university hospitals (P =0.0300). Re-
ferral medical laboratories performed more NSTs (P =0.0022) 
and tended to perform more tacrolimus tests (P =0.0833) than 
university hospitals. Referral medical laboratories tended to have 
a faster TAT for NST than university hospitals (P =0.0606). The 
number of LC-MS/MS instruments moderately correlated with 
the number of laboratory medicine physicians (r=0.5482, P = 
0.0227), strongly correlated with the number of laboratory tech-
Table 2. Laboratory operation/management issues 
Laboratories, N (%)
NST (N=11) Tacrolimus (N=9) Vitamin D (N=9) Plasma metanephrines (N=6)
Test volume (per month) <50 5 (45) 2 (22) 2 (22) 1 (17)
50–100 1 (11) 0 1 (17)
100–200 3 (33) 3 (33) 1 (17)
200–500 1 (11) 2 (22) 2 (33)
500–2,500 2 (22) 2 (22) 1 (17)
2,500–5,000 3 (27) 0 0 0
5,000≤ 3 (27) 0 0 0
Batch size <10 NA 2 (22) 2 (22) 0
10–20 3 (33) 1 (11) 2 (33)
20–50 3 (33) 3 (33) 1 (17)
50≤ 1 (11) 3 (33) 3 (50)
TAT 1 day 0 4 (44) 0 0
<3 days 8 (72) 5 (55) 8 (88) 5 (83)
<7 days 3 (27) 0 0 1 (17)
Testing frequency Daily 6 (55) 6 (66) 3 (33) 0
2–4/week 4 (36) 3 (33) 4 (44) 6 (100)
Once/week 1 (9) 0 2 (22) 0
Other 0 Weekends
5 (55)
0 0
Test order and reporting Manual 3 (27) 6 (67) 6 (67) 5 (83)
Unidirectional interface 8 (73) 3 (33) 3 (33) 1 (17)
Type of reporting Numerical report 0 9 (100) 8 (88) 6 (100)
Text report 11 (100) 3 (33) 2 (22) 1 (17)
Abbreviations: NST, newborn screening test; TAT, turnaround time; NA, not available. 
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nicians (r=0.6793, P =0.0027), and strongly correlated with 
the number of clinical MS tests (r=0.7146, P =0.0013).
LC-MS/MS tests 
Tables 2 and 3 summarize responses on test-specific laboratory 
operational/management issues and methodological issues, re-
spectively.
NSTs represented the highest volume of LC-MS/MS tests, with 
over half of the laboratories performing >2,500 tests per month. 
For tacrolimus, vitamin D, and plasma metanephrine tests, over 
half of the laboratories performed <200 tests per month. Over 
half reported a target TAT of <72 hours for all four tests (Table 2). 
All laboratories used a stable isotope-labeled internal standard 
for the vitamin D and plasma metanephrine tests. However, for 
tacrolimus testing, 78% of the laboratories used a non-isotopic 
internal standard, ascomycin. The majority of laboratories used 
Table 3. Test-specific methodological issues
Laboratories, N (%)
NST (N=11) Tacrolimus (N=9) Vitamin D (N=9) Plasma metanephrines (N=6)
Sample 
pretreatment
Derivatization 6 (55) Protein precipitation 
with acetonitrile
8 (89) Solid phase 
extraction
1 (11) Solid phase 
extraction
5 (83)
Non-derivatized 5 (45) Protein precipitation 
with methanol
1 (11) Liquid-liquid 
extraction
6 (67) Protein 
precipitation
1 (17)
Protein precipitation 3 (33)
Type of reagent Prepared in-house 7 (64) 0 3 (33) 5 (83)
Commercially purchased 5 (45) 9 (100) 3 (33)
Both 3 (33) 1 (17)
Type of internal 
standard
Isotope-labeled NA 2 (22) 9 (100) 6 (100)
Non-isotope-labeled NA 7 (78) 0 0
Type of calibration 
material
Commercially purchased NA 9 (100) 8 (89) 0
Prepared in-house NA 0 1 (11) 6 (100)
Type of matrix Matrix-matched NA 9 (100) 9 (100) 4 (66)
Matrix-unmatched NA 0 0 2 (33)
Calibrators, N 3,4 NA 0 2 (22) 2 (33)
5,6 NA 7 (78) 2 (22) 2 (33)
>6 NA 2 (22) 5 (56) 2 (33)
Type of QC 
material
Commercially purchased 6 (55) 9 (100) 9 (100) 4 (66)
Prepared in-house 1 (9) 0 0 2 (33)
Others CDC 7 (64)
Concentrations of  
QC material [median (range)]
AA 2 (2–4) 3 (3–4) 2 (2–3) 2 (2–3)
AC 2 (2–4)
QC frequency per plate 55 (6) 1 (11) 2 (22) 1 (17)
per run 0 2 (22) 3 (33) 1 (17)
daily 5 (45) 6 (67) 4 (45) 4 (66)
Participating EQA 
programs
KEQAS 11 (100) 9 (100) 5 (63) 6 (100)
CDC 11 (100) NA 1 (13) NA
CAP 0 5 (56) 8 (100) 1 (17)
Others PPFK 10 (92) DEQAS 2 (25) RCPA 2 (33)
VitDQAP 1 (13)
Abbreviations: NST, newborn screening test; NA, not available; CDC, Centers for Disease Control and Prevention; AA, amino acids; AC, acylcarnitines; 
KEQAS, Korean Association of External Quality Assessment Service; PPFK, Planned Population Federation of Korea; CAP, College of American Pathologists; 
DEQAS, Vitamin D External Quality Assessment Scheme; VitDQAP, Vitamin D Metabolites Quality Assurance Program; RCPA, The Royal College of Patholo-
gists of Australasia; EQA, external quality assessment.
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commercial calibrators for the tacrolimus (100%) and vitamin D 
(89%) tests. However, all laboratories used in-house prepared 
calibrators for the plasma metanephrine test. The majority of 
laboratories used matrix-appropriate calibrators for the tacroli-
mus (100%), vitamin D (100%), and plasma metanephrine 
(66%) tests (Table 3). 
The majority of laboratories used commercially available QC 
materials for all four tests. A median of two or three concentra-
tions of QC materials was used, and the most common frequency 
of QC analysis was “per plate” for the NST (55%) and “per day” 
for the tacrolimus (67%), vitamin D (45%), and plasma meta-
nephrine (66%) tests. The majority of laboratories used mean±3 
SDs as the QC acceptability criterion (66%) for the NST, while 
mean±2 SDs was the most commonly used QC acceptability 
criterion for the tacrolimus (83%), vitamin D (66%), and plasma 
metanephrine (66%) tests. The majority of laboratories partici-
pated in the Korean Association of External Quality Assessment 
Service (KEQAS) external quality assessment (EQA) scheme, a 
national laboratory PT scheme, as well as other test-specific glo-
bal EQA schemes. In addition, the majority of laboratories vali-
dated their tests for accuracy, precision, linearity, method com-
parison, carry-over, recovery, lower limit of quantification, ion 
suppression, and matrix effect (Table 4). 
DISCUSSION
This survey summarizes the current practices and characteris-
tics of clinical LC-MS/MS laboratories in Korea. It shows that LC-
MS/MS has been successfully introduced in many clinical labo-
ratories, with major applications in newborn screening, thera-
peutic drug monitoring, endocrinology, and nutritional assess-
ment. The expansion and integration of LC-MS/MS into clinical 
laboratories are reflected in its proportion in EQA programs and 
in the fact that 7% and 2% of all participating laboratories in the 
2018 KEQAS EQA scheme use LC-MS/MS for tacrolimus and 
vitamin D testing, respectively. 
However, the number of clinical LC-MS/MS laboratories in Ko-
rea (19) is still small, only 6% of the total number of clinical lab-
oratories accredited by the KOLAS (305). Further, clinical LC-
MS/MS laboratories are limited to university hospitals (65%) and 
large referral medical laboratories (35%). The proportion of LC-
MS/MS in Korean EQA programs is lower than that in global 
EQA programs (17% and 10% of all participating laboratories 
for tacrolimus and vitamin D tests, respectively) [5]. Therefore, 
considering the global growth of clinical LC-MS/MS tests, there 
is still room for further expansion of LC-MS/MS in Korea.
The original sample preparation methods for the LC-MS/MS 
NST used butyl esterification (derivatization). However, with the 
improved sensitivity of MS instruments, it is possible to detect 
amino acids and acylcarnitines as their native free acids (non-
derivatized). We found that the proportion of derivatization and 
non-derivatized sample preparation methods used was similar, 
in accordance with recent CDC NST QC data summaries [6]. 
Protein precipitation is the most commonly used method for ex-
tracting immunosuppressants because it is simple, cheap, and 
less time-consuming [7]. For the vitamin D tests, 67% and 33% 
of all laboratories used liquid-liquid extraction and protein pre-
cipitation methods, respectively, similar to the proportions re-
ported in the vitamin D EQA Scheme (DEQAS) data [8]. To ana-
lyze plasma metanephrines, solid phase extraction has been the 
sample preparation method of choice [9]. In the present survey, 
all but one laboratory used solid phase extraction for sample 
preparation. 
The addition of an internal standard to samples before analy-
sis represents the single most valuable method enhancement 
that MS can offer [10]. All responding laboratories used meth-
ods that included the use of an internal standard. The majority 
of laboratories used a stable isotope-labeled form of the mea-
sured analyte. However, for tacrolimus, a non-isotopic internal 
standard, ascomycin, was used by the majority of laboratories. 
Table 4. Components of method validation
Laboratories, N (%)
NST  
(N=9)
Tacrolimus 
(N=8)
Vitamin D 
(N=9)
Plasma 
metanephrines 
(N=6)
Accuracy 6 (67) 7 (88) 9 (100) 6 (100)
Precision 9 (100) 8 (100) 9 (100) 6 (100)
Linearity 5 (56) 8 (100) 9 (100) 6 (100)
Comparison 6 (67) 8 (100) 9 (100) 4 (67)
Carry-over 6 (67) 7 (88) 9 (100) 6 (100)
Recovery 4 (44) 7 (88) 8 (89) 6 (100)
Limit of detection 3 (33) 3 (38) 4 (44) 3 (50)
Limit of quantification 2 (22) 8 (100) 8 (89) 6 (100)
Ion suppression and 
matrix effect
2 (22) 7 (88) 6 (67) 5 (83)
Batch size 1 (11) 1 (13) 1 (11) 1 (17)
SST 0 1 (13) 2 (22) 1 (17)
Interferences 0 3 (38) 3 (33) 2 (33)
Stability 0 6 (75) 2 (22) 3 (50)
Abbreviations: SST, system suitability test; NST, newborn screening test.
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Although a recent study did not observe any differences between 
the use of ascomycin and an isotope-labeled internal standard, 
tacrolimus-13C,D2 [11], other studies reported better results us-
ing tacrolimus-13C,D2 than ascomycin [12]. With the recent avail-
ability of commercial isotope-labeled internal standards for im-
munosuppressants (e.g., Chromsystems, Munich, Germany, or 
Recipe, Munich, Germany), the use of isotope-labeled internal 
standards in immunosuppressant LC-MS/MS tests is likely to in-
crease in the near future.
Regarding quality assurance and QC for LC-MS/MS, the CLSI 
document C62-A suggests that a minimum of two concentrations 
of QC materials should be measured at least every 24 hours dur-
ing patient testing [10]. We found that at least two concentra-
tions of QC materials were measured for each LC-MS/MS test, 
and all laboratories were using QC acceptability criteria based 
on their own established QC means and SDs derived from re-
petitive analysis of control materials. All laboratories reported 
participation in one or more EQA programs. As EQA is one of 
the most preferred methods for assessing test accuracy, these 
laboratories reported using LC-MS/MS within a quality frame-
work that addresses both internal and external quality assur-
ance. 
One of the potential obstacles preventing the adoption of LC-
MS/MS in routine clinical laboratories is the seemingly overwhelm-
ing method validation requirements required to meet the guide-
lines for clinical applications. Although there are multiple guide-
lines for the validation of bioanalytical methods [13-15], includ-
ing the CLSI C62-A [10], regulatory requirements differ somewhat 
across countries and laboratory accreditation agencies. In this 
regard, the development of regional/national guidelines for LC-
MS/MS validation for clinical laboratories that address regional 
regulations could facilitate the use of LC-MS/MS in medium-
sized community hospitals and regional clinical laboratories in 
Korea. 
This study has some limitations. Because this survey was an 
initiative of the CMSRC of the KSCC, it focused primarily on LC-
MS/MS testing in clinical chemistry applications. Thus, other ar-
eas of clinical MS, such as gas chromatography-MS, inductively 
coupled plasma MS, and matrix-assisted laser desorption ion-
ization time-of-flight MS (MALDI-TOF MS), in clinical microbiol-
ogy were not assessed. Another limitation was the fact that the 
number of responding laboratories was relatively low, making it 
difficult to draw definitive conclusions.
However, this survey is the first to describe various aspects of 
LC-MS/MS in clinical laboratories in Korea. Furthermore, it is 
important to understand the current status of clinical LC-MS/MS 
laboratory practices to form a basis upon which future harmoni-
zation and advancements can be made. Further studies attempt-
ing to harmonize and enhance the analytical robustness of LC-
MS methods on a nationwide basis will be necessary. 
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